Fred Hassan (photo [1]) may have his hands full these days, defending Vytorin and Zetia while cutting jobs and costs. But at least his pockets are full, too. The Schering-Plough CEO chalked up more than $30 million in 2007 compensation, according to the company's proxy. (The Associated Press totes up $24.7 million, because it leaves out pension benefits.)
The details: Salary came to $1.67 million, up from $1.65 million in 2006. He got no bonus, but did rake in $18.4 million in stock and options, more than double the amount he brought in last year. His $608,000 in perks included $146,680 for personal security.
One interesting note in the proxy: If the stock performance as of March 31, 2008 had been used to calculate compensation (rather than December 31, 2007) then Hassan's "five-year transformational incentive" would have paid out exactly nothing. The Vytorin controversy thus puts a big chunk of Hassan and his fellow Schering-Plough bigwigs' pay at risk, the proxy states. Duly noted.
- find Schering's proxy [2] at the SEC
- check out Pharmalot's calculations [3]
- see the Associated Press numbers [4]
- get the specifics [5] on Hassan's at-risk pay at the Shearlings Plowed blog
Related Articles:
A turbulent week for Fred Hassan [6]
Hassan bullish on Schering-Plough [7]
Schering-Plough laying off 5,500 [8]
Links:
[1] http://www.fiercebiotech.com/pages/schering-plough-ceo-fred-hassan
[2] http://www.sec.gov/Archives/edgar/data/310158/000095012308004524/y50020def14a.htm#114
[3] http://www.pharmalot.com/2008/04/the-good-old-days-hassan-got-247m-in-07/
[4] http://money.cnn.com/news/newsfeeds/articles/apwire/f4ba4630e0aaaa3ea1024eacc2216b6c.htm
[5] http://shearlingsplowed.blogspot.com/2008/04/we-have-winner-ceo-hassan-made-3032.html
[6] http://www.fiercepharma.com/story/a-turbulent-week-for-fred-hassan/2008-04-07
[7] http://www.fiercebiotech.com/story/spotlight-hassan-bullish-on-schering-plough/2007-01-30
[8] http://www.fiercepharma.com/story/schering-plough-laying-off-5500/2008-04-03?utm_medium=nl&utm_source=link